Volume 29, Number 11—November 2023
Research
Duration of Enterovirus D68 RNA Shedding in the Upper Respiratory Tract and Transmission among Household Contacts, Colorado, USA
Hai Nguyen-Tran
, Careese Thompson, Molly Butler, Kristen R. Miller, Laura Pyle, Sarah Jung, Shannon Rogers, Terry Fei Fan Ng, Janell Routh, Samuel R. Dominguez, and Kevin Messacar
, Careese Thompson, Molly Butler, Kristen R. Miller, Laura Pyle, Sarah Jung, Shannon Rogers, Terry Fei Fan Ng, Janell Routh, Samuel R. Dominguez, and Kevin Messacar
Table 2
Selected medical history of study participants in study of EV-D68 RNA shedding in the upper respiratory tract and associated clinical characteristics, Colorado, USA*
| Comorbidity† | No. (%) participants |
|||
|---|---|---|---|---|
| All participants, N = 25 | EV-D68–positive primary participants, n = 9 | EV-D68–positive household contacts, n = 5 | EV-D68–negative household contacts, n = 11 | |
| Asthma | 4 (16.0) | 1 (11.1) | 2 (40.0) | 1 (9.1) |
| History of prematurity | 3 (12.0) | 2 (22.12) | 1 (20.0) | 0 |
| Chronic heart disease | 1 (4.0) | 1 (11.1) | 0 | 0 |
| Chronic lung disease | 1 (4.0) | 1 (11.1) | 0 | 0 |
| Other reported history‡ | 4 (16.0) | 2 (22.2) | 1 (20.0) | 1 (9.1) |
| None reported | 15 (60.0) | 5 (55.6) | 1 (20.0) | 9 (81.8) |
*EV, enterovirus. †Comorbidities are not mutually exclusive. ‡Other includes Trisomy 21, chromosomal abnormality, developmental delay, cavernous malformation, obesity, hypothyroidism, or nephrolithiasis.
Page created: October 02, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.